Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.

This Month's Profile Group, BioHub At Alderley Park, features profiles of Absynth Biologics, Blueberry Therapeutics, Molplex Pharmaceuticals, and OncoTherics. Plus these Start-Ups Across Health Care: Centerline Biomedical, Laurimed, and Portal Instruments.

Absynth Biologics Ltd. aims to harness patients’ own immune systems in the fight to prevent and treat bacterial infections; its platform identifies proteins on the cell membranes of bacteria that are essential for their survival, and are highly conserved. Combinations of these proteins, with additive or synergistic potential, are then used to create vaccines and antibodies that may inhibit bacterial activity, as well as engage the immune system to attack and eliminate the infection.

Once an R&D site for AstraZeneca, the BioHub at Alderley Park is now home to a number of emerging biotechs. Profiles of Absynth Biologics, Blueberry Therapeutics, Molplex, and OncoTherics.